The European Medicines Agency (EMA) is organising a one-hour webinar on 1 December 2016, starting at 14:30, which aims to showcase to pharmaceutical companies the benefits of working with the European Network for Paediatric Research at EMA (Enpr-EMA) and the clinical research networks it represents in the development of medicines for children.
The speakers at the event are Mark Turner, Chair of Enpr-EMA and Co-Chair Irmgard Eichler who will outline the role of EMA in this network and the practical support Enpr-EMA can offer to developers of paediatric medicines.
You can follow the event live on EMA’s webpage by following these instructions. The webinar recording will be made available on the event page.
Enpr-EMA was set up to facilitate the conduct of clinical studies in children. It is an umbrella network of 39 national and international networks recognised for their paediatric research experience. It acts as a platform for sharing good practices as well as a pan-European voice to foster high-quality, ethical research on the safety and effectiveness of medicines for children.
Enpr-EMA focuses on:
- fostering high-quality, ethical research on the quality, safety and efficacy of medicines for use in children;
- helping with the recruitment of patients for clinical trials;
- enabling collaboration between networks and stakeholders;
- avoiding unnecessary duplication of studies;
- building up scientific and administrative competence at a European level;
- promoting European Commission framework programme applications.